Combined, the technologies create a smart, automated process for insulin delivery based on real-time glucose data.
The companies launched their automated insulin delivery (AID) system in Germany. They intend to offer it in additional European countries in 2023.
“Our FreeStyle Libre portfolio is already helping to improve the lives of 4.5 million people around the world who are living with diabetes,” said Jared Watkin, SVP of Abbott’s diabetes care business. “We’re partnering with diabetes and digital health technology leaders like Ypsomed and CamDiab to deliver new innovative solutions that make diabetes care as easy as possible, so people can spend less time worrying about their diabetes and more time living.”